No great news from Geron, but there was alot of good news stories on stem cells. I believe in the science more each day. Can Geron come up with a FDA approved blockbuster before they run out of money. It will be very very close. GRN1005 is there best shot. If the data from the previously completed Phase 1 trail in metastatic brain cancer are confirmed and depending upon the strength of the data the product candidate may have an opportunity for early marketing approval. I will feel better about Geron's viability if and when they find a partner with deep pockets.
The high for the week was $2.43 on Nov. 8 and the low was $2.21 on Nov. 10. The volume is very low. Five day avg. volume is 922,200 shares, ten day avg. volume 1,069,566 shares and the three month avg 1,446,080 shares.
I didn't get any $3 calls my bid was to low.
Good luck in this rigged casino,
No comments:
Post a Comment